nach oben

Current Hepatology Reports

Erschienen in:

19.07.2017 | Portal Hypertension (J Abraldes and E Tsochatzis, Section Editors)

Cardiovascular Effects of a Transjugular Intrahepatic Portosystemic Shunt in Patients with Cirrhosis

verfasst von: Troels M. Busk, Søren Møller, Flemming Bendtsen

Erschienen in: Current Hepatology Reports | Ausgabe 3/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Insertion of a transjugular intrahepatic portosystemic shunt (TIPS) has proven effective in alleviating complications to portal hypertension such as refractory ascites and variceal bleeding in patients with cirrhosis. Moreover, it increases survival in selected patient groups. However, TIPS also causes marked circulatory changes and a central concern has been whether this could negatively affect cardiac function. Therefore, this review aims to critically discuss our knowledge on cardiovascular effects of a TIPS in cirrhosis.

Recent Findings

These suggest that TIPS does not worsen cardiac function. Careful cardiac evaluation prior to TIPS is, however, a prerequisite in order to prevent cardiac complications after TIPS insertion.

Summary

The focus on cirrhotic cardiomyopathy has raised the awareness on specific procedures such as TIPS. Thus, previous studies have demonstrated that TIPS seemingly worsens cardiac function with a negative effect on ascites clearance and survival. However, recent studies have not been able to establish this deleterious interplay and the overall frequency of cardiac failure after TIPS still remains low. Hence, TIPS seems to be safe with regard to cardiac function in patients with cirrhosis.

Rossle M, Gerbes AL. TIPS for the treatment of refractory ascites, hepatorenal syndrome and hepatic hydrothorax: a critical update. Gut. 2010;59(7):988–1000.PubMedCrossRef

•• Sauerbruch T, Mengel M, Dollinger M, Zipprich A, Rossle M, Panther E, et al. Prevention of rebleeding from esophageal varices in patients with cirrhosis receiving small-diameter stents versus hemodynamically controlled medical therapy. Gastroenterology. 2015;149(3):660–8. An important study demonstrating the efficacy of TIPS on variceal bleeding. PubMedCrossRef

Garcia-Pagan JC, Caca K, Bureau C, Laleman W, Appenrodt B, Luca A, et al. Early use of TIPS in patients with cirrhosis and variceal bleeding. N Engl J Med. 2010 Jun 24;362(25):2370–9.PubMedCrossRef

•• Bureau C, Thabut D, Oberti F, Dharancy S, Carbonell N, Bouvier A, et al. Transjugular intrahepatic portosystemic shunts with covered stents increase transplant-free survival of patients with cirrhosis and recurrent ascites. Gastroenterology. 2017;152(1):157–63. An important study showing that TIPS increases survival in patients with recurrent ascites. PubMedCrossRef

Salerno F, Camma C, Enea M, Rossle M, Wong F. Transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis of individual patient data. Gastroenterology. 2007;133(3):825–34.PubMedCrossRef

Wong W, Liu P, Blendis L, Wong F. Long-term renal sodium handling in patients with cirrhosis treated with transjugular intrahepatic portosystemic shunts for refractory ascites. Am J Med. 1999;106(3):315–22.PubMedCrossRef

Wong F, Sniderman K, Liu P, Blendis L. The mechanism of the initial natriuresis after transjugular intrahepatic portosystemic shunt. Gastroenterology. 1997;112(3):899–907.PubMedCrossRef

Gerbes AL, Gulberg V, Waggershauser T, Holl J, Reiser M. Renal effects of transjugular intrahepatic portosystemic shunt in cirrhosis: comparison of patients with ascites, with refractory ascites, or without ascites. Hepatology. 1998;28(3):683–8.PubMedCrossRef

Salerno F, Cazzaniga M, Pagnozzi G, Cirello I, Nicolini A, Meregaglia D, et al. Humoral and cardiac effects of TIPS in cirrhotic patients with different “effective” blood volume. Hepatology. 2003;38(6):1370–7.PubMed

10.

Moller S, Henriksen JH. Cirrhotic cardiomyopathy. J Hepatol. 2010;53(1):179–90.PubMedCrossRef

11.

Ruiz-del-Arbol L, Monescillo A, Arocena C, Valer P, Gines P, Moreira V, et al. Circulatory function and hepatorenal syndrome in cirrhosis. Hepatology. 2005;42(2):439–47.PubMedCrossRef

12.

Ruiz-del-Arbol L, Urman J, Fernandez J, Gonzalez M, Navasa M, Monescillo A, et al. Systemic, renal, and hepatic hemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology. 2003;38(5):1210–8.PubMedCrossRef

13.

Krag A, Bendtsen F, Henriksen JH, Moller S. Low cardiac output predicts development of hepatorenal syndrome and survival in patients with cirrhosis and ascites. Gut. 2010 Jan;59(1):105–10.PubMedCrossRef

14.

Colombato LA, Spahr L, Martinet JP, Dufresne MP, Lafortune M, Fenyves D, et al. Haemodynamic adaptation two months after transjugular intrahepatic portosystemic shunt (TIPS) in cirrhotic patients. Gut. 1996;39(4):600–4.PubMedPubMedCentralCrossRef

15.

Huonker M, Schumacher YO, Ochs A, Sorichter S, Keul J, Rossle M. Cardiac function and haemodynamics in alcoholic cirrhosis and effects of the transjugular intrahepatic portosystemic stent shunt. Gut. 1999;44(5):743–8.PubMedPubMedCentralCrossRef

16.

Lotterer E, Wengert A, Fleig WE. Transjugular intrahepatic portosystemic shunt: short-term and long-term effects on hepatic and systemic hemodynamics in patients with cirrhosis. Hepatology. 1999;29(3):632–9.PubMedCrossRef

17.

•• Saugel B, Mair S, Meidert AS, Phillip V, Messer M, Nennstiel S, et al. The effects of transjugular intrahepatic portosystemic stent shunt on systemic cardiocirculatory parameters. J Crit Care. 2014;29(6):1001–5. Recent study demonstrating the beneficial effects of TIPS on cardiac and renal function. PubMedCrossRef

18.

Busk TM, Bendtsen F, Moller S. Cardiac and renal effects of a transjugular intrahepatic portosystemic shunt in cirrhosis. Eur J Gastroenterol Hepatol. 2013;25(5):523–30.PubMedCrossRef

19.

Rabie RN, Cazzaniga M, Salerno F, Wong F. The use of E/A ratio as a predictor of outcome in cirrhotic patients treated with transjugular intrahepatic portosystemic shunt. Am J Gastroenterol. 2009;104(10):2458–66.PubMedCrossRef

20.

Cazzaniga M, Salerno F, Pagnozzi G, Dionigi E, Visentin S, Cirello I, et al. Diastolic dysfunction is associated with poor survival in patients with cirrhosis with transjugular intrahepatic portosystemic shunt. Gut. 2007;56(6):869–75.PubMedPubMedCentralCrossRef

21.

Trevisani F, Merli M, Savelli F, Valeriano V, Zambruni A, Riggio O, et al. QT interval in patients with non-cirrhotic portal hypertension and in cirrhotic patients treated with transjugular intrahepatic porto-systemic shunt. J Hepatol. 2003;38(4):461–7.PubMedCrossRef

22.

Wannhoff A, Hippchen T, Weiss CS, Friedrich K, Rupp C, Neumann-Haefelin C, et al. Cardiac volume overload and pulmonary hypertension in long-term follow-up of patients with a transjugular intrahepatic portosystemic shunt. Aliment Pharmacol Ther. 2016;43(9):955–65.PubMedCrossRef

23.

Moller S, Bendtsen F. Cirrhotic multiorgan syndrome. Dig Dis Sci. 2015;60(11):3209–25.PubMedCrossRef

24.

Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodes J. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology. 1988;8(5):1151–7.PubMedCrossRef

25.

Moller S, Henriksen JH. Cardiovascular complications of cirrhosis. Gut. 2008;57(2):268–78.PubMedCrossRef

26.

Kiszka-Kanowitz M, Henriksen JH, Moller S, Bendtsen F. Blood volume distribution in patients with cirrhosis: aspects of the dual-head gamma-camera technique. J Hepatol. 2001;35(5):605–12.PubMedCrossRef

27.

Henriksen JH, Bendtsen F, Sorensen TI, Stadeager C, Ring-Larsen H. Reduced central blood volume in cirrhosis. Gastroenterology. 1989;97(6):1506–13.PubMedCrossRef

28.

Moller S, Henriksen JH, Bendtsen F. Central and noncentral blood volumes in cirrhosis: relationship to anthropometrics and gender. Am J Physiol Gastrointest Liver Physiol. 2003;284(6):G970–9.PubMedCrossRef

29.

Krag A, Moller S, Pedersen EB, Henriksen JH, Holstein-Rathlou NH, Bendtsen F. Impaired free water excretion in child C cirrhosis and ascites: relations to distal tubular function and the vasopressin system. Liver Int. 2010;30(9):1364–70.PubMedCrossRef

30.

Moller S, Bendtsen F, Henriksen JH. Determinants of the renin-angiotensin-aldosterone system in cirrhosis with special emphasis on the central blood volume. Scand J Gastroenterol. 2006;41(4):451–8.PubMedCrossRef

31.

Moller S, Iversen JS, Henriksen JH, Bendtsen F. Reduced baroreflex sensitivity in alcoholic cirrhosis: relations to hemodynamics and humoral systems. Am J Physiol Heart Circ Physiol. 2007;292(6):H2966–72.PubMedCrossRef

32.

Moller S, Iversen JS, Krag A, Bie P, Kjaer A, Bendtsen F. Reduced baroreflex sensitivity and pulmonary dysfunction in alcoholic cirrhosis: effect of hyperoxia. Am J Physiol Gastrointest Liver Physiol. 2010;299(3):G784–90.PubMedCrossRef

33.

Moller S, Bernardi M. Interactions of the heart and the liver. Eur Heart J. 2013;34(36):2804–11.PubMedCrossRef

34.

• Wiese S, Hove JD, Bendtsen F. Moller S. Cirrhotic cardiomyopathy: pathogenesis and clinical relevance. Nat Rev Gastroenterol Hepatol. 2014;11(3):177–86. Recent review on cirrhotic cardiomyopathy. PubMedCrossRef

35.

Wong F, Girgrah N, Graba J, Allidina Y, Liu P, Blendis L. The cardiac response to exercise in cirrhosis. Gut. 2001;49(2):268–75.PubMedPubMedCentralCrossRef

36.

Gines P, Uriz J, Calahorra B, Garcia-Tsao G, Kamath PS, Del Arbol LR, et al. Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis. Gastroenterology. 2002;123(6):1839–47.PubMedCrossRef

37.

Braverman AC, Steiner MA, Picus D, White H. High-output congestive heart failure following transjugular intrahepatic portal-systemic shunting. Chest. 1995;107(5):1467–9.PubMedCrossRef

38.

Krag A, Bendtsen F, Burroughs AK, Moller S. The cardiorenal link in advanced cirrhosis. Med Hypotheses. 2012;79(1):53–5.PubMedCrossRef

39.

Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2015;16(3):233–70.PubMedCrossRef

40.

Jensen MT, Sogaard P, Andersen HU, Bech J, Fritz HT, Biering-Sorensen T, et al. Global longitudinal strain is not impaired in type 1 diabetes patients without albuminuria: the Thousand & 1 study. JACC Cardiovasc Imaging. 2015;8(4):400–10.PubMedCrossRef

41.

Nagueh SF, Smiseth OA, Appleton CP, Byrd BF III, Dokainish H, Edvardsen T, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2016;29(4):277–314.PubMedCrossRef

42.

Zambruni A, Trevisani F, Caraceni P, Bernardi M. Cardiac electrophysiological abnormalities in patients with cirrhosis. J Hepatol. 2006;44(5):994–1002.PubMedCrossRef

43.

Henriksen JH, Gulberg V, Fuglsang S, Schifter S, Bendtsen F, Gerbes AL, et al. Q-T interval (QT (C)) in patients with cirrhosis: relation to vasoactive peptides and heart rate. Scand J Clin Lab Invest. 2007;67(6):643–53.PubMedCrossRef

44.

Ytting H, Henriksen JH, Fuglsang S, Bendtsen F, Moller S. Prolonged Q-T (c) interval in mild portal hypertensive cirrhosis. J Hepatol. 2005;43(4):637–44.PubMedCrossRef

45.

Henriksen JH, Fuglsang S, Bendtsen F, Christensen E, Moller S. Dyssynchronous electrical and mechanical systole in patients with cirrhosis. J Hepatol. 2002 Apr;36(4):513–20.PubMedCrossRef

46.

Voiosu A, Wiese S, Voiosu T, Bendtsen F, Moller S. Bile acids and cardiovascular function in cirrhosis. Liver Int. 2017.

47.

Fede G, D’Amico G, Arvaniti V, Tsochatzis E, Germani G, Georgiadis D, et al. Renal failure and cirrhosis: a systematic review of mortality and prognosis. J Hepatol. 2012;56(4):810–8.PubMedCrossRef

48.

Gines P, Schrier RW. Renal failure in cirrhosis. N Engl J Med. 2009;361(13):1279–90.PubMedCrossRef

49.

Cavallin M, Fasolato S, Marenco S, Piano S, Tonon M, Angeli P. The treatment of hepatorenal syndrome. Dig Dis. 2015;33(4):548–54.PubMedCrossRef

50.

Angeli P, Gines P, Wong F, Bernardi M, Boyer TD, Gerbes A, et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. Gut. 2015;64(4):531–7.PubMedCrossRef

51.

Wong F, Nadim MK, Kellum JA, Salerno F, Bellomo R, Gerbes A, et al. Working Party proposal for a revised classification system of renal dysfunction in patients with cirrhosis. Gut. 2011;60(5):702–9.PubMedCrossRef

52.

Moller S, Bendtsen F, Henriksen JH. Effect of volume expansion on systemic hemodynamics and central and arterial blood volume in cirrhosis. Gastroenterology. 1995;109(6):1917–25.PubMedCrossRef

53.

Adebayo D, Morabito V, Davenport A, Jalan R. Renal dysfunction in cirrhosis is not just a vasomotor nephropathy. Kidney Int. 2015;87(3):509–15.PubMedCrossRef

54.

Gungor G, Ataseven H, Demir A, Solak Y, Gaipov A, Biyik M, et al. Neutrophil gelatinase-associated lipocalin in prediction of mortality in patients with hepatorenal syndrome: a prospective observational study. Liver Int. 2014;34(1):49–57.PubMedCrossRef

55.

• Busk TM, Bendtsen F, Moller S. Hepatorenal syndrome in cirrhosis: diagnostic, pathophysiological, and therapeutic aspects. Expert Rev Gastroenterol Hepatol. 2016; 1–9. Recent review on renal dysfunction in cirrhosis.

56.

Stadlbauer V, Wright GA, Banaji M, Mukhopadhya A, Mookerjee RP, Moore K, et al. Relationship between activation of the sympathetic nervous system and renal blood flow autoregulation in cirrhosis. Gastroenterology. 2008;134(1):111–9.PubMedCrossRef

57.

Boyer TD, Haskal ZJ. The role of transjugular intrahepatic portosystemic shunt (TIPS) in the Management of Portal Hypertension: update 2009. Hepatology. 2010;51(1):306.PubMedCrossRef

58.

•• Fili D, Falletta C, Luca A, Hernandez BC, Clemenza F, Miraglia R, et al. Circulatory response to volume expansion and transjugular intrahepatic portosystemic shunt in refractory ascites: relationship with diastolic dysfunction. Dig Liver Dis. 2015;47(12):1052–8. Recent study demonstrating that TIPS insertion is safe in cirrhosis with regards to cardiac function. PubMedCrossRef

59.

Schwartz JM, Beymer C, Althaus SJ, Larson AM, Zaman A, Glickerman DJ, et al. Cardiopulmonary consequences of transjugular intrahepatic portosystemic shunts: role of increased pulmonary artery pressure. J Clin Gastroenterol. 2004;38(7):590–4.PubMedCrossRef

60.

Stanley AJ, Redhead DN, Bouchier IA, Hayes PC. Acute effects of transjugular intrahepatic portosystemic stent-shunt (TIPSS) procedure on renal blood flow and cardiopulmonary hemodynamics in cirrhosis. Am J Gastroenterol. 1998;93(12):2463–8.PubMedCrossRef

61.

Colombato L. The role of transjugular intrahepatic portosystemic shunt (TIPS) in the management of portal hypertension. J Clin Gastroenterol. 2007;41(Suppl 3):S344–51.PubMedCrossRef

62.

Brensing KA, Textor J, Perz J, Schiedermaier P, Raab P, Strunk H, et al. Long term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II study. Gut. 2000;47(2):288–95.PubMedPubMedCentralCrossRef

63.

Guevara M, Gines P, Bandi JC, Gilabert R, Sort P, Jimenez W, et al. Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems. Hepatology. 1998;28(2):416–22.PubMedCrossRef

64.

Sanyal AJ, Genning C, Reddy KR, Wong F, Kowdley KV, Benner K, et al. The North American study for the treatment of refractory ascites. Gastroenterology. 2003;124(3):634–41.PubMedCrossRef

65.

Merli M, Valeriano V, Funaro S, Attili AF, Masini A, Efrati C, et al. Modifications of cardiac function in cirrhotic patients treated with transjugular intrahepatic portosystemic shunt (TIPS). Am J Gastroenterol. 2002;97(1):142–8.PubMedCrossRef

66.

Fagiuoli S, Bruno R, Debernardi VW, Schepis F, Vizzutti F, Toniutto P, et al. Consensus conference on TIPS management: techniques, indications, contraindications. Dig Liver Dis. 2017;49(2):121–37.PubMedCrossRef

67.

Rudler M, Cluzel P, Corvec TL, Benosman H, Rousseau G, Poynard T, et al. Early-TIPSS placement prevents rebleeding in high-risk patients with variceal bleeding, without improving survival. Aliment Pharmacol Ther. 2014;40(9):1074–80.PubMedCrossRef

68.

Pieper CC, Sprinkart AM, Nadal J, Hippe V, Meyer C, Schild HH, et al. Postinterventional passive expansion of partially dilated transjugular intrahepatic portosystemic shunt stents. J Vasc Interv Radiol. 2015;26(3):388–94.PubMedCrossRef

69.

•• Allegretti AS, Ortiz G, Cui J, Wenger J, Bhan I, Chung RT, et al. Changes in kidney function after transjugular intrahepatic portosystemic shunts versus large-volume paracentesis in cirrhosis: a matched cohort analysis. Am J Kidney Dis. 2016;68(3):381–91. Recent paper showing the beneficial effect of TIPS on renal function in cirrhosis. PubMedCrossRef

Titel: Cardiovascular Effects of a Transjugular Intrahepatic Portosystemic Shunt in Patients with Cirrhosis
verfasst von: Troels M. Busk
Søren Møller
Flemming Bendtsen
Publikationsdatum: 19.07.2017
Verlag: Springer US
Erschienen in: Current Hepatology Reports / Ausgabe 3/2017
Elektronische ISSN: 2195-9595
DOI: https://doi.org/10.1007/s11901-017-0362-x

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

16.04.2024 | Chronische Herzinsuffizienz | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Cardiovascular Effects of a Transjugular Intrahepatic Portosystemic Shunt in Patients with Cirrhosis

Abstract

Purpose of Review

Recent Findings

Summary

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Sind Betablocker auch für ältere herzschwache Personen nützlich?

Kein Abstrich bei chronischen Wunden ohne Entzündungszeichen!

Manche Gestagene können das Risiko für Meningeome erhöhen

Stillende Frauen haben geringeres kardiovaskuläres Risiko

Update Innere Medizin

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2017

Management and Treatment of Chronic HBV and HCV Co-Infection and the Impact of Anti-Viral Therapy

Risk Stratification with Noninvasive Tools in Patients with Compensated Cirrhosis

Genetic Factors Influencing Drug-Induced Liver Injury: Do They Have a Role in Prevention and Diagnosis?

Patient Selection for Transjugular Intrahepatic Portosystemic Stent Shunt (TIPSS) Insertion in Variceal Bleeding and Refractory Ascites

Idiopathic Non-cirrhotic Portal Hypertension and Close Entities: a Need for Clarifying Terminology

The Landscape of Patient Access to Direct Acting Antivirals by Payer Within the United States Healthcare System

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Sind Betablocker auch für ältere herzschwache Personen nützlich?

Kein Abstrich bei chronischen Wunden ohne Entzündungszeichen!

Manche Gestagene können das Risiko für Meningeome erhöhen

Stillende Frauen haben geringeres kardiovaskuläres Risiko

Update Innere Medizin